December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Prognosis of Panretinal Photocoagulation with More Than 3 Weeks Intervals
Author Affiliations & Notes
  • N Takeda
    Department of Ophthalmology Intnl Med Ctr of Japan Tokyo Japan
  • Footnotes
    Commercial Relationships   N. Takeda, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3461. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N Takeda; Prognosis of Panretinal Photocoagulation with More Than 3 Weeks Intervals . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3461.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Photocoagulation is a very effective treatment for diabetic retinopathy, but in some cases visual loss occurs due to postoperative macular edema. To avoid visual loss after photocoagulation, we performed panretinal photocoagulation with longer intervals than usual. Methods: Fourty-one eyes performed panretinal photocoagulation with more than 3 weeks intervals were analyzed. Results: Decrease of visual acuity more than 2 lines was observed in 0.0% of the cases at less than 1 year follow-up period. Decrease of final visual acuity was observed in 31.7% and there was no statistical significance compared to the cases panretinal photocoagulation was performed with less than 3 weeks intervals. But the incidence of cases with poor prognosis was low (2.4%) at final examination. Conclusion: Panretinal photocoagulation with more than 3 weeks intervals did not affect the final visual prognosis but lessened the visual loss in early period after photocoagulation.

Keywords: 388 diabetic retinopathy • 454 laser • 353 clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.